drugset / Trial / NCT01746745

A Study of LY2940680 in Healthy Participants

NCT01746745

Phase 1 Completed 6 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelOther

Summary

This is a single dose study of radiolabelled LY2940680 taken by mouth in healthy participants to study how the body absorbs and removes LY2940680 from the blood. This study is for research purposes only and is not intended to treat any medical condition.

Timeline

Start
2013-01
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject taladegib Small molecule 100 mg Oral

Indications

No indication recorded.